Agenebio

announcements

May 2, 2019

T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon

Hosted by Lindsay Czarniak, the Ninth Annual Great Ladies Luncheon & Fashion Show honored T.J. Oshie of the Washington Capitals and Dr. Michela Gallagher, founder and CEO of AgeneBio.

announcements

January 11, 2019

New Funding Focuses on Prevention

The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.

announcements

September 17, 2018

Dr. Michela Gallagher Wins Alzheimer’s Drug Discovery Foundation’s Prestigious Goodes Prize

Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101.

announcements

January 8, 2018

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

blog

March 6, 2017

Prevention: A Key to Conquering Alzheimer’s

Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials.

blog

February 21, 2017

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

blog

February 3, 2015

Early-Stage Dementia Treatment Headed to Phase 3 Clinical Trial

ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment.

announcements

January 28, 2015

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.